Symbicort Turbuhaler approved for asthma in Japan
This article was originally published in Scrip
Executive Summary
AstraZeneca's inhaled combination asthma product Symbicort has been formally approved in Japan for the maintenance treatment of bronchial asthma in patients aged 16 years or older.